Grand Pharmaceutical Group Management

Management criteria checks 3/4

Grand Pharmaceutical Group's CEO is Chao Zhou, appointed in Jun 2021, has a tenure of 3.42 years. total yearly compensation is HK$1.87M, comprised of 90.8% salary and 9.2% bonuses, including company stock and options. directly owns 0.01% of the company’s shares, worth €190.11K. The average tenure of the management team and the board of directors is 3.4 years and 3.4 years respectively.

Key information

Chao Zhou

Chief executive officer

HK$1.9m

Total compensation

CEO salary percentage	90.8%
CEO tenure	3.4yrs
CEO ownership	0.01%
Management average tenure	3.4yrs
Board average tenure	3.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chao Zhou's remuneration changed compared to Grand Pharmaceutical Group's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	HK$2b
Mar 31 2024	n/a	n/a	HK$2b
Dec 31 2023	HK$2m	HK$2m	HK$2b

Compensation vs Market: Chao's total compensation ($USD240.61K) is below average for companies of similar size in the German market ($USD1.64M).

Compensation vs Earnings: Insufficient data to compare Chao's compensation with company performance.

CEO

Chao Zhou (34 yo)

3.4yrs

Tenure

HK$1,873,000

Compensation

Mr. Chao Zhou serves as Chief Executive Officer of Grand Pharmaceutical Group Limited (formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited) since June 01, 2021 and serves as its Ex...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Weikun Tang	Executive Chairman	3.4yrs	HK$2.89m	0.021% € 391.3k
Chao Zhou	CEO & Executive Director	3.4yrs	HK$1.87m	0.010% € 190.1k
Guang Yang	Executive Director	1.4yrs	HK$25.00k	no data
Liu Hu	Investor Relations Director	no data	no data	no data
Chit Lam	Executive Director	less than a year	no data	0.017% € 309.9k
Tin Chung Foo	Company Secretary	13.2yrs	no data	no data
Xiaofeng Shi	Chairman of Grand Pharm (China)	no data	no data	no data
Xiaojie Chen	Vice President	no data	no data	no data

3.4yrs

Average Tenure

51yo

Average Age

Experienced Management: MX6A's management team is considered experienced (3.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Weikun Tang	Executive Chairman	3.4yrs	HK$2.89m	0.021% € 391.3k
Chao Zhou	CEO & Executive Director	1.4yrs	HK$1.87m	0.010% € 190.1k
Guang Yang	Executive Director	1.4yrs	HK$25.00k	no data
Chit Lam	Executive Director	less than a year	no data	0.017% € 309.9k
Xiaofeng Shi	Chairman of Grand Pharm (China)	no data	no data	no data
Tosi Wan So	Independent Non-Executive Director	19.7yrs	HK$180.00k	no data
Yebi Hu	Independent Non-Executive Director	5.9yrs	HK$60.00k	no data
Geng Pei	Independent Non-Executive Director	13.5yrs	HK$100.00k	no data
Guofan Xie	Director of Grand Pharm (China)	30.8yrs	no data	no data
Zhang Bangguo	Director of Zhejiang Xianju Xianle Pharmaceutical Company Limited	no data	no data	no data
Li Xing	Non-Executive Director	less than a year	no data	no data

3.4yrs

Average Tenure

57yo

Average Age

Experienced Board: MX6A's board of directors are considered experienced (3.4 years average tenure).

Grand Pharmaceutical Group Management

Management criteria checks 3/4

Key information

Recent management updates

Grand Pharmaceutical Group Limited Appoints Lam Chit Yee Jessica as Executive Director

Grand Pharmaceutical Group Limited Announces Executive Changes

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Executive Chairman recently bought €44k worth of stock

Less than half of directors are independent

Recent updates

Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA

National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

New minor risk - Share price stability

Grand Pharmaceutical Group Limited Appoints Lam Chit Yee Jessica as Executive Director

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

Grand Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

Grand Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 19, 2024

Grand Pharmaceutical Group Limited Announces Executive Changes

Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment

Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.26 per share

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Executive Chairman recently bought €44k worth of stock

Dividend of HK$0.26 announced

Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Full year 2023 earnings released: EPS: HK$0.54 (vs HK$0.59 in FY 2022)

Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024

Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002)

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing

Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint

Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently

First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022)

Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate

Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023

Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China

Less than half of directors are independent

Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director

Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces Board Changes

Upcoming dividend of HK$0.14 per share at 2.8% yield

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray

Full year 2022 earnings released: EPS: HK$0.59 (vs HK$0.68 in FY 2021)

National Medical Products Administration of the People's Republic of China Accepts Grand Pharmaceutical Group Limited's Investigational New Drug Applications of the Group Three Innovative Products in China

Grand Pharmaceutical Group Limited Conducts Clinical Trials of its Innovative Oral Small Molecule 3Cl Protease Inhibitor GS221 Against COVID-19

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces NMPA Approves Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX591-CDx

First half 2022 earnings released: EPS: HK$0.20 (vs HK$0.34 in 1H 2021)

Grand Pharmaceutical Group Limited Announces Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Approved by NMPA

Less than half of directors are independent

First half 2022 earnings released

Grand Pharmaceutical Group Limited Provides Unaudited Earnings Guidance for Six Months Ended 30 June 2022

Grand Pharmaceutical Group Announces Clinical Trial Applications in China for Global Innovative Radionuclide-Drug Conjugates TLX591-CDX AND TLX250-CDX Accepted by NMPA

Grand Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 10, 2022

Less than half of directors are independent

Executive Director recently bought €64k worth of stock

Grand Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2021

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial of Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment in China

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Now 21% undervalued after recent price drop

Sirtex Medical and Grand Pharmaceutical Group Limited Receive NDA Approval of SIR-Spheres® Y-90 Resin Microspheres in China from the National Medical Products Administration

First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020)

First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020)

China Grand Pharmaceutical and Healthcare Holdings Limited (SEHK:512) agreed to acquire 22.2% interest in CoRISMA MCS Systems, Inc for $12 million.

Less than half of directors are independent

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure